Leading minds.
Rigor and innovation.
Better Outcomes for patients.
Who We Are
World-Class Team
Behind every transformative therapy is a team that dares to re-imagine the future of brain health. At Synphatec, world-class drug hunters, clinician-scientists, and biotech veterans converge around a single mission: turn complex neuroscience into life-changing medicines.
CNS Strategic Focus
Our focus on CNS disorders reflects a strategic commitment to therapeutic areas with significant patient impact and substantial scientific opportunity. We channel every resource toward the conditions where innovative biology can make the greatest difference.
2021
Founded
7
Programs
¥100M+
RMB Raised
CNS
Specialization
Development Timeline
Our journey from founding to clinical advancement
Company Founded
The founding team achieved breakthrough progress in the mechanistic research of depression and Alzheimer’s disease, and the i-NaS drug screening platform was initially established.
SP-101 entered Pre-PCC stage.
Angel Financing Round
The company was founded and successively received hundreds-of-millions scale fundings from renowned investment institutions. We established preclinical, clinical, operational, and advisory teams.
SP-101 obtained IND approval and initiated Phase I clinical trials.
SP-102 completed PCC and preliminary preclinical validation.
Clinical Trial Milestone & Series Financing
Complete Phase I clinical trials and POC studies for SP-101.
Complete IIT studies and preliminary human POC for SP-201.
Add 2–3 new clinical programs.
Compliance & Disclaimer
Important Notice: All products and drug candidates of Synphatec are currently in preclinical or clinical trial stages and have not been approved by the National Medical Products Administration (NMPA) or other regulatory authorities. They are not intended for clinical treatment use.
The information provided on this website is for reference purposes only and does not constitute any investment advice, partnership offer, or clinical efficacy claim. All clinical trial-related content is presented objectively based on trial stage and indication, without exaggeration of efficacy or cure rates.